Coronaviruses and their therapy
Identifieur interne : 004696 ( Main/Merge ); précédent : 004695; suivant : 004697Coronaviruses and their therapy
Auteurs : Bart L. Haagmans [Pays-Bas] ; Albert D. M. E. Osterhaus [Pays-Bas]Source :
- Antiviral research [ 0166-3542 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000451
- to stream PascalFrancis, to step Curation: 000539
- to stream PascalFrancis, to step Checkpoint: 000495
Links to Exploration step
Pascal:06-0491674Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Coronaviruses and their therapy</title><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0491674</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0491674 INIST</idno><idno type="RBID">Pascal:06-0491674</idno><idno type="wicri:Area/PascalFrancis/Corpus">000451</idno><idno type="wicri:Area/PascalFrancis/Curation">000539</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000495</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000495</idno><idno type="wicri:doubleKey">0166-3542:2006:Haagmans B:coronaviruses:and:their</idno><idno type="wicri:Area/Main/Merge">004696</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Coronaviruses and their therapy</title><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Coronavirus</term><term>Fusion inhibitor</term><term>Review</term><term>Severe acute respiratory syndrome</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term><term>Article synthèse</term><term>Syndrome respiratoire aigu sévère</term><term>Antiviral</term><term>Coronavirus</term><term>Inhibiteur d'entrée</term><term>inhibiteur de réplication</term><term>Inhibiteur de fusion</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name></noRegion><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004696 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004696 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:06-0491674
|texte= Coronaviruses and their therapy
}}
| This area was generated with Dilib version V0.6.33. |  |